TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu ...

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the c ...

Just over four months have passed since the publication of my last article , "Why Investors Should Watch Teva Despite Regional Risks," and during that time, the Teva Pharmaceutical Industries Limited (NYSE: TEVA ) share priceWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, a ...

Just over four months have passed since the publication of my last article , "Why Investors Should Watch Teva Despite Regional Risks," and during that time, the Teva Pharmaceutical Industries Limited (NYSE: TEVA ) share priceWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, a ...

Question-and-Answer SessionJason GerberryBofA Securities, Research Division So Richard, thanks for joining us. It's been an interesting year and some interesting events over the next 12 to 18 months, which we'll get into. But maybe just to kick things off, if you can just talk a little bit about capital allocation, right? It's kind of central to what Teva's doing. Net debt paydown is obviously very important but you also have a very interesting innovative new product story. And so how do you keep feeding th ...

Teva Pharmaceutical Industries (NYSE:TEVA) 2025 Conference September 24, 2025 04:00 AM ET Company ParticipantsRichard Francis - CEOConference Call ParticipantsJason Gerberry - AnalystJason GerberryGoing to get going with our next company presenter at the BofA Healthcare Conference here in London. Pleased to be introducing Teva Pharmaceuticals and CEO, Richard Francis. My name is Jason Gerberry. I'm one of the SMID-cap Biotech and Specialty Pharma analysts here at BofA. Richard, thanks for joining us. It's b ...

Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eric Hughes - Executive VP of Global R&D and Chief Medical Officer Christine Fox - Executive VP of U.S. Commercial BusinessPresentation Operator Welcome to the Olanzapine LAI TEV-'749 Phase III SOLARIS Data Presentation Conference Call. My name is Elliot, and I'll be coordinating your call today. [Operator Instructions]. I would now like to hand over to Christopher Stevo. Please go ahead. Christopher StevoSenior V ...

Key Takeaways Alvotech revenues jumped over 200% in H1 2025, led by Simlandi and Selarsdi sales.Teva expects up to 12 biosimilar launches in the US and Europe between 2025 and 2027.ALVO shares are down 14% YTD, while TEVA has dropped 39%, both lagging the industry.Both Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) operate in the biosimilar space, but their business models differ significantly.ALVO has built its revenue model around partnerships, relying on alliances with regional players to bring products ...

公司动态 - 公司召开奥氮平长效注射剂TEV-'749三期SOLARIS研究数据发布会电话会议 [1] - 公司高管Christopher Stevo担任投资者关系与竞争情报高级副总裁 Eric Hughes担任全球研发执行副总裁兼首席医疗官 [2][4] - 公司在圣地亚哥精神科会议上公布了SOLARIS三期临床试验的安全性和有效性数据 [4] 研发进展 - TEV-'749是针对精神分裂症研发的奥氮平长效注射剂制剂 [4] - 公司拥有强大的神经科学研发传承 [4] - 三期SOLARIS研究已进入数据公布阶段 [1][4]

Teva Pharmaceutical Industries (NYSE:TEVA) Update / Briefing September 22, 2025 11:00 AM ET Company ParticipantsLes Sulewski - VP, Biotech Equity ResearchMatthew Toal - AssociateChristopher Stevo - SVP,Head of Investor RelationsEric Hughes - EVP Global R&D and Chief Medical OfficerChris Fox - EVP US CommercialChristoph Correll - Professor of Psychiatry and Chair of Child & Adolescent PsychiatryConference Call ParticipantsJason Gerberry - Managing Director and Equity Research AnalystDavid Amsellem - Managing ...